Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
11.98
+0.08 (0.67%)
At close: May 15, 2026, 4:00 PM EDT
12.00
+0.02 (0.17%)
After-hours: May 15, 2026, 7:58 PM EDT

Tenax Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
23.0923.716.795.015.687.58
Research & Development
38.5332.6712.713.235.3825.15
Total Operating Expenses
61.6256.3919.498.2311.0532.73
Operating Income
-61.62-56.39-19.49-8.23-11.05-32.73
Interest Income
3.753.821.910.48--
Interest Expense
--0.020.02-0-0
Other Non-Operating Income (Expense)
-0.04-0.0300.06-0.01-0.25
Total Non-Operating Income (Expense)
3.713.791.940.57-0.01-0.26
Pretax Income
-57.91-52.6-17.56-7.66-11.07-32.98
Net Income
57.9152.617.67.71-11.05-32.47
Net Income to Common
57.9152.617.67.71-11.05-32.47
Net Income Growth
23.52%198.82%128.27%---
Shares Outstanding (Basic)
413915000
Shares Outstanding (Diluted)
413915000
Shares Change (YoY)
74.17%156.80%6046.86%91.74%--
EPS (Basic)
-1.40-1.34-1.15-31.04-600.71-31.56
EPS (Diluted)
-1.40-1.34-1.15-31.04-600.71-31.56
Shares Outstanding
24.289.313.420.30.030.02
Free Cash Flow
-38.14-35.8-14.81-5.9-11.39-10.86
Free Cash Flow Per Share
-0.92-0.91-0.97-23.76-87.89-83.83
EBITDA
-61.62-56.39-19.49-8.23-10.94-32.62
EBIT
-61.62-56.39-19.49-8.23-11.05-32.73
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q